002864 盘龙药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.8178.91111.75612.32311.339
总资产报酬率 ROA (%)2.7465.4466.2057.4757.566
投入资产回报率 ROIC (%)3.5197.3789.02511.00610.800

边际利润分析
销售毛利率 (%)62.43957.91958.12358.27862.293
营业利润率 (%)13.79813.75012.62712.67914.169
息税前利润/营业总收入 (%)12.13011.56311.91211.37514.143
净利润/营业总收入 (%)13.05311.37310.58710.65412.098

收益指标分析
经营活动净收益/利润总额(%)93.768103.655104.739106.23496.849
价值变动净收益/利润总额(%)-0.173-1.204-0.0950.0005.950
营业外收支净额/利润总额(%)7.153-4.341-3.224-3.206-0.509

偿债能力分析
流动比率 (X)3.8933.4921.6422.1862.509
速动比率 (X)3.7023.3311.5372.0332.316
资产负债率 (%)28.89527.00050.92139.3160.367
带息债务/全部投入资本 (%)3.3830.88526.4707.5884.802
股东权益/带息债务 (%)2,688.94210,562.201262.7601,152.3001,904.953
股东权益/负债合计 (%)245.767269.98194.555151.326168.845
利息保障倍数 (X)-4.443-7.162-37.118-12.501311.215

营运能力分析
应收账款周转天数 (天)147.418151.879148.706138.304140.523
存货周转天数 (天)85.29475.12171.20164.73188.507